XTRA:BAYNPharmaceuticals
How Investors May Respond To Bayer (XTRA:BAYN) Balancing Roundup Risks With New Biotech Partnerships
Bayer and Vanderbilt University Medical Center previously entered a five-year collaboration to advance therapies from target discovery through IND application, initially targeting cardiovascular and kidney diseases by combining Bayer’s research capabilities with Vanderbilt’s extensive BioVU genetic and clinical datasets.
At the same time, Bayer’s outlook has been influenced by the U.S. Supreme Court’s decision to review a key Roundup case and the FDA’s orphan designation for a BlueRock...